「for」の検索結果
119件：111～115件目を表示
-
お知らせ | 千寿製薬株式会社
ough TRPV1 Inhibition（PDF） December 22, 2025 Obtained manufacturing and marketing approval in Japan for Avarept® Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Rece...
https://www.senju.co.jp/english/news/ -
お知らせ | 千寿製薬株式会社
ough TRPV1 Inhibition（PDF） December 22, 2025 Obtained manufacturing and marketing approval in Japan for Avarept® Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Rece...
http://www.senju.co.jp/english/news/ -
Milestones in Our History | About Senju | SENJU Pharmaceutical
ished the company in Tennoji-ku, Osaka with start-up capital of 195,000 yen. July Injection Product for Neutropenia, "PANILTIN", sales launched 1949 February Reishin Tanimura became the Pres...
https://www.senju.co.jp/english/about/history.html -
Product Development Policy | Research & Development | SENJU Pharmaceutica
obial ophthalmic solutions, non-steroidal anti-inflammatory ophthalmic solutions, therapeutic drugs for spring catarrh (orphan drugs), therapeutic drugs for glaucoma, ocular hypertension, etc. We also...
http://www.senju.co.jp/english/rd/policy/ -
Research and Development System | Research & Development | SENJU Pharmaceutica
All things in nature have a reason for being. Today’s common sense is not common sense tomorrow. This is our motto. Senju Pharmaceutical has unique research systems, such as international joint resear...
http://www.senju.co.jp/english/rd/about/